First Approved Kinase Inhibitor for AML
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3MutationNew England Journal of Medicine, 2017
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood, 2005
- Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Cancer Cell, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Structural organization of the bcr gene and its role in the Ph′ translocationNature, 1985
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973